One thing after another, SK Chemicals’ journey to overcome Prevenar 13 patents
Although SK Chemicals is about to commercialized its first 13-valent pneumococcal vaccine for the first time in Korea, it seems it will take more time to sell it in the market.
This is because it has to overcome the patent of ‘Prevenar 13(Pfizer),’ the original, to sell it.
According to the ind...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
